Victoria Socha

DocwireNews

Treatment for patients who develop severe hypertension during hospitalization is not guideline dependent, according to Lama Ghazi, MD, PhD, and colleagues at Yale University, New Haven, Connecticut. Treatment with intravenous (IV) antihypertensives could lead to more acute blood pressure reductions and worse outcomes compared with oral medications. The researchers conducted a study designed to examine the effect on clinical outcomes of treatment overall and by treatment route in patients who develop severe hypertension during hospitalization.Results of the multi-hospital, retrospective study were reported during a poster session at the American Society of Nephrology Kidney Week 2022. The poster was titled Antihypertensive Treatment and Clinical Outcomes Among Patients Who Develop Severe Hypertension During Hospitalization.The study cohort included adults admitted for reasons other than hypertension who developed severe hypertension during the hospitalization. Severe hypertension was defined as systolic blood pressure &ge;180 mm Hg or diastolic blood pressure &ge;110 mm Hg. The association between treatment and clinical outcomes was examined using overlap propensity score weighted Cox models.Of 224,265 patient hospitalizations, 9% developed severe hypertension and 40% were treated. Of those treated, 21% received IV hypertensive medications and 72% received oral hypertensives. Compared with patients who received oral hypertensives, those who received IV antihypertensive treatment were more likely to be female (60% vs 54%), less likely to be Hispanic or Latino (9% vs 12%), and were less likely to have comorbidities such as hypertension (79% vs 88%), and diabetes (42% vs 52%).Patients in the IV medications group were also less likely to be admitted to the medical ward (71% vs 87%), have higher estimated glomerular filtration rate (63 mL/min/1.73 m2 vs 55 mL/min/1.73 m2) on admission, have higher blood pressure on admission (168/68 mm Hg vs 153/79 mm Hg), and higher blood pressure at the time of development of severe hypertension (188/92 mm Hg vs 185/88 mm Hg).Compared with patients who did not receive treatment for severe hypertension, those who received IV treatment had higher risk of myocardial injury, acute kidney injury, and death. Patients who received oral hypertensives had lower risk of death compared with those who received no treatment.In conclusion, the researchers said, &ldquo;IV antihypertensive treatment was associated with worse clinical outcomes and therefore oral antihypertensives should be considered as the more preferable alternative for treatment of severe hypertension without acute end organ damage.&rdquo;Source: Ghazi L, Nugent J, Greenberg JH, Bakhoum CY, Wilson, FP. Antihypertensive treatment and clinical outcomes among patients who develop severe hypertension during hospitalization. FR-PO752. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 4, 2022; Orlando. Florida.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Treating Patients Hospitalized With Severe Hypertension

Part of NephTimes Diseases and Conditions

Diabetes and Hypertension

Treatment for patients who develop severe hypertension during hospitalization is not guideline dependent, according to Lama Ghazi, MD, PhD, and colleagues at Yale University, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe